Philip H Keiser
Affiliation: University of Texas Southwestern Medical Center
- Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentPhilip H Keiser
University of Texas Southwestern Medical Center, Dallas, Texas, USA
BMC Infect Dis 5:2. 2005..Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-HIV medications without lipid effects...
- Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database studyPhilip H Keiser
Department of Internal Medicine, Division of Infectious Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390 9113, USA
Int J STD AIDS 19:561-2. 2008....
- The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysisRichard H Haubrich
University of California at San Diego, San Diego, California, USA
AIDS 16:F33-40. 2002..To evaluate the clinical significance of hypersusceptibility to non-nucleoside reverse transcriptase inhibitors (NNRTI)...
- A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575Richard H Haubrich
University of California, San Diego, California, USA
AIDS 19:295-302. 2005..To assess phenotype susceptibility testing (PHENO) with standard of care (SOC) to improve antiretroviral therapy...